Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN66,9266,98-0,30
Msft-2,45
Nokia3,3843,43-0,69
IBM-8,25
Mercedes-Benz Group AG73,1473,16-1,08
PFE-3,84
26.04.2024 1:27:00
Indexy online
AD Index online
select
AD Index online
 

  • 25.04.2024
Ropharma (RORPH.BX, Bucharest)
Závěr k 25.4.2024 Změna (%) Změna (RON) Objem obchodů (RON)
0,186 -3,63 -0,01 10 278
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.04.2024
Popis společnosti
Obecné informace
Název společnostiRopharma SA
TickerRPH
Kmenové akcie:Ordinary Shares
RICRORPH.BX
ISINROIAFRACNOR4
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.06.2019
Počet zaměstnanců k 31.12.2016 1 353
Akcie v oběhu k 30.06.2019 511 267 413
MěnaRON
Kontaktní informace
UliceStr. Iuliu Maniu, Nr. 55, Etaj 1
MěstoBRASOV
PSČ500091
ZeměRomania
Kontatní osoba 
Funkce kontaktní osoby 
Telefon40 268 547 230
Fax40268547231

Business Summary: Ropharma SA is a Romania-based company engaged in the pharmaceutical industry. The Company is active in the wholesale and retail of drugs. It also has a production facility of over-the-counter drugs and dietary supplements. The Company sells pharmaceutical products through its pharmacies located in the Romanian cities of Iasi, Vaslui, Suceava, Botosani, Bacau, Neamt, Vrancea, Mures, Harghita, Sibiu and Brasov. Through its distribution center, the Company provides drugs, food supplements, skin cosmetics and other products. It manufactures pharmaceutical products under the brand names Aesculap, Bioef and Eurofarmaco. As of December 31, 2011, Ropharma SA had six subsidiaries: Romanita-Farm Srl, Ropharma Production Srl, Aesculap Prod Srl, Ergo Farm Srl, Drops Farm Srl and Europharm Trading 7 SA.
Financial Summary: BRIEF: For the six months ended 30 June 2019, Ropharma SA revenues increased 45% to RON415.2M. Net income applicable to common stockholders decreased 58% to RON2.2M. Revenues reflect Income from Sales increase of 48% to RON383.5M, Revenue From Rendering Medical Services increase of 15% to RON31.8M. Net income was offset by Social expenses increase of 16% to RON41.4M (expense), Depreciation and Amortization increase from RON4.9M to RON10M (expense).
Odvětvová klasifikace
TRBC2009Retail - Drugs
TRBC2012Retail - Drugs with Grocery
RBSS2004Retail - Drugs
MGINDUSTRYRetail (Drugs)
MGSECTORServices
NAICSPharmacies and Drug Stores
NAICSDrug, Drug Proprietaries and Druggists' Sundries Wholesalers
NAICSPharmaceutical Preparation Manufacturing
SICDrug Stores/proprietary Stores
SICDrugs/proprietaries/sundries
SICPharmaceutical Preparations



  • Poslední aktualizace: 26.04.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerMihai Miron58
Chief Financial Officer, DirectorAlin Radasanu4601.01.2010
Director of Human Resources, DirectorDanut Ene5001.01.2012